Mertens LS - Search Results

1

Superior efficacy of neoadjuvant chemotherapy and radical cystectomy in cT3-4aN0M0 compared to cT2N0M0 bladder cancer.

Hermans TJN, Voskuilen CS, Deelen M, Mertens LS, Horenblas S, Meijer RP, Boormans JL, Aben KK, van der Heijden MS, Pos FJ, de Wit R, Beerepoot LV, Verhoeven RHA, van Rhijn BWG. Hermans TJN, et al. Among authors: mertens ls. Int J Cancer. 2019 Mar 15;144(6):1453-1459. doi: 10.1002/ijc.31833. Epub 2018 Sep 24. Int J Cancer. 2019. PMID: 30155893 Free article.

2

Catheter-assisted 18F-FDG-PET/CT imaging of primary bladder cancer: a prospective study.

Mertens LS, Bruin NM, Vegt E, de Blok WM, Fioole-Bruining A, van Rhijn BW, Horenblas S, Vogel WV. Mertens LS, et al. Nucl Med Commun. 2012 Nov;33(11):1195-201. doi: 10.1097/MNM.0b013e3283567473. Nucl Med Commun. 2012. PMID: 22781846 Clinical Trial.

3

Differences in histopathological evaluation of standard lymph node dissections result in differences in nodal count but not in survival.

Mertens LS, Meijer RP, van Werkhoven E, Bex A, van der Poel HG, van Rhijn BW, Meinhardt W, Horenblas S. Mertens LS, et al. World J Urol. 2013 Oct;31(5):1297-302. doi: 10.1007/s00345-012-0916-z. Epub 2012 Aug 9. World J Urol. 2013. PMID: 22875170

4

Carboplatin based induction chemotherapy for nonorgan confined bladder cancer--a reasonable alternative for cisplatin unfit patients?

Mertens LS, Meijer RP, Kerst JM, Bergman AM, van Tinteren H, van Rhijn BW, Horenblas S. Mertens LS, et al. J Urol. 2012 Oct;188(4):1108-13. doi: 10.1016/j.juro.2012.06.018. Epub 2012 Aug 15. J Urol. 2012. PMID: 22901581

5

Extravasation of intravesical chemotherapy for non-muscle-invasive bladder cancer.

Mertens LS, Meinhardt W, Rier WB, Nooter RI, Horenblas S. Mertens LS, et al. Urol Int. 2012;89(3):332-6. doi: 10.1159/000341900. Epub 2012 Sep 5. Urol Int. 2012. PMID: 22965138

6

FDG-positron emission tomography/computerized tomography for monitoring the response of pelvic lymph node metastasis to neoadjuvant chemotherapy for bladder cancer.

Mertens LS, Fioole-Bruining A, van Rhijn BW, Kerst JM, Bergman AM, Vogel WV, Vegt E, Horenblas S. Mertens LS, et al. J Urol. 2013 May;189(5):1687-91. doi: 10.1016/j.juro.2012.11.009. Epub 2012 Nov 6. J Urol. 2013. PMID: 23142689

7

Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.

Mertens LS, Fioole-Bruining A, Vegt E, Vogel WV, van Rhijn BW, Horenblas S. Mertens LS, et al. BJU Int. 2013 Oct;112(6):729-34. doi: 10.1111/bju.12109. Epub 2013 Jun 24. BJU Int. 2013. PMID: 23790129

8

Biomarkers for assessing therapeutic response in bladder cancer.

Mertens LS, Neuzillet Y, Horenblas S, van Rhijn BW. Mertens LS, et al. Arch Esp Urol. 2013 Jun;66(5):495-504. Arch Esp Urol. 2013. PMID: 23793767 Review.

9

Detecting primary bladder cancer using delayed (18)F-2-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography imaging after forced diuresis.

Mertens LS, Fioole-Bruining A, Vegt E, Vogel WV, van Rhijn BW, Horenblas S. Mertens LS, et al. Indian J Nucl Med. 2012 Jul;27(3):145-50. doi: 10.4103/0972-3919.112718. Indian J Nucl Med. 2012. PMID: 23919066 Free PMC article.

10

Occult lymph node metastases in patients with carcinoma invading bladder muscle: incidence after neoadjuvant chemotherapy and cystectomy vs after cystectomy alone.

Mertens LS, Meijer RP, Meinhardt W, van der Poel HG, Bex A, Kerst JM, van der Heijden MS, Bergman AM, Horenblas S, van Rhijn BW. Mertens LS, et al. BJU Int. 2014 Jul;114(1):67-74. doi: 10.1111/bju.12447. Epub 2014 Jan 17. BJU Int. 2014. PMID: 24053889

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

103 results

Search Page